Delving into the Latest Updates on Materia Medica Holding Research And Production Company with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Immune System Diseases

Monoclonal antibody

Biological products

Interferons

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Monoclonal antibody	5
Interferons	1
Biological products	1

Top 5 Target	Count

TNF-α(Tumor necrosis factor α)	2
IFNGR(Interferon gamma receptor)	1
KLK3(Prostate-specific antigen)	1
AT1R(Angiotensin II Receptor Type 1)	1

We studied the effects of Ergoferon on the production of antiviral cytokine IL-2 by type 1 CD4⁺T cells. Preincubation of Jurkat cells with Ergoferon increased IL-2 secretion by these cells after stimulation with phorbol 12-myristate 13-acetate/ionomycine in comparison with the placebo group. The data prove that Ergoferon is capable of activating cell cascades involved in the realization of the antiviral immune response.

01 Jan 2017·Bulletin of Experimental Biology and MedicineQ4 · MEDICINE

Effects of Release-Active Antibodies to CD4 Receptor on the Level of lck-Kinase in Cultured Mononuclear Cells from Human Peripheral Blood

Q4 · MEDICINE

Article

Author: Petrova, N V ; Khaitov, M R ; Tarasov, S A ; Emel'yanova, A G ; Morozov, S G ; Grechenko, V V ; Gorbunov, E A ; Epshtein, O I ; Shilovskii, I P

For evaluation of effects of release-active antibodies to CD4 on cultured lymphocytes from human peripheral blood, we measured intracellular content of lck-kinase cell-based ELISA. In cells treated with release-active antibodies to CD4, the content of intracellular lck-kinase significantly (p<0.01) decreased in comparison with the control (purified water processed in a similar way). Phytohemagglutinin had no effect on the concentration of lck-kinase in cells. The decrease in the content of CD4-associated lck protein suggests that the preparation enhanced intracellular coupling of lck-kinase with T-cell receptor and potentiated T-cell immune response.

01 Jan 2005·International journal of tissue reactions

A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.

Article

Author: Tcherevkova, E V ; Epstein, O I ; Petrov, V I ; Martyushev-Poklad, A V ; Babayeva, A R ; Dugina, J L ; Sergeeva, S A

Artrofoon (oral ultra-low doses of antibodies to TNF-alpha is a novel drug approved by the Russian Ministry of Health for the treatment of rheumatoid arthritis (RA). The aim of this study was to assess clinical efficacy and safety of artrofoon in RA compared with diclofenac. In a 6-month, randomized, open-label, comparative trial, 60 patients with active RA (eight men and 52 women aged 23 to 62, mean disease duration 10 years) received artrofoon (8 tablets daily, n = 30) or diclofenac (100 mg daily, n = 30). RA signs and symptoms as well as serum levels of inflammatory markers were evaluated before treatment and at months 1, 3 and 6. Most patients in the artrofoon group showed a 20% improvement in major RA symptoms by the end of the study. The clinical effect rose gradually reaching maximum at month 6. In the artrofoon group, 57% of the patients achieved an American College of Rheumatology (ACR) 20% criteria (ACR20) by month 6 versus 20% of those receiving diclofenac. In some patients in the artrofoon arm, serum proinflammatory cytokine levels significantly decreased (> or = 25% reduction). Diclofenac produced a less pronounced clinical effect, and no changes in cytokine profile. Unlike conventional nonsteroidal anti-inflammatory drugs, artrofoon produced no adverse effects and the overall tolerability and safety were excellent. A half-dose treatment with artrofoon (4 tablets daily) was able to sustain clinical improvements over a 6-month follow-up period. To conclude, artrofoon is a safe and effective treatment for rheumatoid arthritis that acts by influencing the inflammatory process.

100 Deals associated with Materia Medica Holding Research And Production Company

Login to view more data

100 Translational Medicine associated with Materia Medica Holding Research And Production Company

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

6

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Kolofort ( TNF-α )	Irritable Bowel Syndrome More	Approved
Rengalin	Cough More	Approved
Afala ( KLK3 )	Prostatic Cancer More	Approved
Ergoferon(Materia Medica Holding Research And Production Company)	Influenza, Human More	Approved
Anti-tumour necrosis factor-alpha antibody(Materia Medica Holding Research And Production Company) ( TNF-α )	Osteoarthritis More	Approved